Omeros Corp
NASDAQ:OMER

Watchlist Manager
Omeros Corp Logo
Omeros Corp
NASDAQ:OMER
Watchlist
Price: 16.38 USD -4.63% Market Closed
Market Cap: 1.2B USD

Operating Margin
Omeros Corp

0%
Current
0%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-129.4m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Omeros Corp
NASDAQ:OMER
1.1B USD N/A
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
498.9B USD
27%
CH
Roche Holding AG
SIX:ROG
259.1B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
208.8B GBP
24%
US
Merck & Co Inc
NYSE:MRK
264.8B USD
38%
CH
Novartis AG
SIX:NOVN
207.2B CHF
33%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
143.2B USD
29%
No Stocks Found

Omeros Corp
Glance View

Omeros Corp. operates as a biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 213 full-time employees. The company went IPO on 2009-10-08. The firm is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, immunologic diseases and cancers. The Company’s lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and coronavirus (COVID-19). OMS906, the Company’s inhibitor of MASP-3, the alternative pathway of complement, is in a Phase 1 clinical trial.

OMER Intrinsic Value
9.26 USD
Overvaluation 43%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-129.4m
/
Revenue
0
What is the Operating Margin of Omeros Corp?

Based on Omeros Corp's most recent financial statements, the company has Operating Margin of 0%.

Back to Top